{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:18:01Z","timestamp":1791580681912,"version":"4.3.4"},"reference-count":240,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01162","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T04:59:43Z","timestamp":1573102783000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Lourdes M.","family":"Mendez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan R.","family":"Posey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Pandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med."},{"key":"B2","volume-title":"SEER Cancer Statistics Review","author":"Noone","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1053\/j.seminoncol.2008.04.015","article-title":"Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality","volume":"35","author":"Meijer","year":"2008","journal-title":"Semin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fonc.2018.00213","article-title":"Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity","volume":"8","author":"Lamble","year":"2018","journal-title":"Front Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mr\u00f3zek","year":"2012","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3324\/haematol.13299","article-title":"Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling","volume":"94","author":"Verhaak","year":"2009","journal-title":"Haematologica."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJMoa040465","article-title":"Prognostically useful gene-expression profiles in acute myeloid leukemia","volume":"350","author":"Valk","year":"2004","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1182\/blood-2014-07-591461","article-title":"Mutational spectrum of myeloid malignancies with inv(3)\/t(3;3) reveals a predominant involvement of RAS\/RTK signaling pathways","volume":"125","author":"Gr\u00f6schel","year":"2015","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1084\/jem.20151775","article-title":"Genetically distinct leukemic stem cells in human CD34\u2212 acute myeloid leukemia are arrested at a hemopoietic precursor-like stage","volume":"213","author":"Quek","year":"2016","journal-title":"J Exp Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell."},{"key":"B24","first-page":"1525","article-title":"Adoptive immunotherapy of acute leukemia: experimental and clinical results","volume":"25","author":"Mathe","year":"1965","journal-title":"Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.critrevonc.2016.04.020","article-title":"Harnessing the immune system in acute myeloid leukaemia","volume":"103","author":"Austin","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","author":"Papaioannou","year":"2016","journal-title":"Ann Transl Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science."},{"key":"B30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1182\/blood-2016-10-744441","article-title":"Neutrophils acquire antigen presentation capacity to memory CD4+ T cells in vitro and ex vivo","volume":"129","author":"Vono","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nri.2017.28","article-title":"Monocyte differentiation and antigen-presenting functions","volume":"17","author":"Jakubzick","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1189\/jlb.1MR1014-502R","article-title":"Neutrophil plasticity: acquisition of phenotype and functionality of antigen-presenting cell","volume":"98","author":"Takashima","year":"2015","journal-title":"J Leukoc Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nri3754","article-title":"Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?","volume":"14","author":"Kambayashi","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.molmed.2017.08.007","article-title":"Neoantigen vaccines pass the immunogenicity test","volume":"23","author":"Linette","year":"2017","journal-title":"Trends Mol Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CJI.0b013e3181b8f4ce","article-title":"Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods","volume":"33","author":"Kremser","year":"2010","journal-title":"J Immunother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"15825","DOI":"10.1073\/pnas.0908358106","article-title":"Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation","volume":"106","author":"Ho","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B39","doi-asserted-by":"publisher","first-page":"368ra171","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci Transl Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2017-11-785873","article-title":"Vaccine therapy in hematologic malignancies","volume":"134","author":"Avigan","year":"2018","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00262-015-1713-5","article-title":"STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol Immunother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"8716","DOI":"10.18632\/oncotarget.2368","article-title":"IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus","volume":"5","author":"Chen","year":"2014","journal-title":"Oncotarget."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity","volume":"111","author":"Movahedi","year":"2008","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukaemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2014-09-600643","article-title":"Arginine dependence of acute myeloid leukaemia blast proliferation: a novel therapeutic target","volume":"125","author":"Mussai","year":"2015","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2016.143180","article-title":"Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner","volume":"101","author":"Al-Matary","year":"2016","journal-title":"Haematologica."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1412910","DOI":"10.1080\/2162402X.2017.1412910","article-title":"Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects","volume":"7","author":"Yang","year":"2018","journal-title":"Oncoimmunology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2816498","DOI":"10.1155\/2019\/2816498","article-title":"CD4(+)CD25(high)CD127(low\/-)FoxP(3) (+) regulatory T-cell population in acute leukemias: a review of the literature","volume":"2019","author":"Niedzwiecki","year":"2019","journal-title":"J Immunol Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/icb.2010.137","article-title":"Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns","volume":"89","author":"Miyara","year":"2011","journal-title":"Immunol Cell Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.molmed.2007.01.003","article-title":"Natural regulatory T cells: mechanisms of suppression","volume":"13","author":"Miyara","year":"2007","journal-title":"Trends Mol Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/cyto.b.21349","article-title":"Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes","volume":"90","author":"Aggarwal","year":"2016","journal-title":"Cytometry B."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","article-title":"Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia","volume":"15","author":"Szczepanski","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1600-0609.2005.00537.x","article-title":"Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients","volume":"75","author":"Wang","year":"2005","journal-title":"Eur J Haematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2172-11-38","article-title":"Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells","volume":"11","author":"Ersvaer","year":"2010","journal-title":"BMC Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25791","article-title":"Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia","volume":"129","author":"Shenghui","year":"2011","journal-title":"Int J Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"E200","DOI":"10.3390\/jcm8020200","article-title":"Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)","volume":"8","author":"Hofmann","year":"2019","journal-title":"J Clin Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","author":"Keir","year":"2007","journal-title":"Curr Opin Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol Immunother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kronig","year":"2014","journal-title":"Eur J Haematol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/eji.201242814","article-title":"Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands","volume":"43","author":"Dolen","year":"2013","journal-title":"Eur J Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MOH.0000000000000158","article-title":"Targeting immune checkpoints in lymphoma","volume":"22","author":"Ansell","year":"2015","journal-title":"Curr Opin Hematol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia."},{"key":"B69","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget."},{"key":"B70","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/0008-5472.CAN-12-2179","article-title":"Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance","volume":"73","author":"Berrien-Elliott","year":"2013","journal-title":"Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.tips.2015.03.006","article-title":"Arginase: an old enzyme with new tricks","volume":"36","author":"Caldwell","year":"2015","journal-title":"Trends Pharmacol Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fimmu.2014.00483","article-title":"Fatty acids, lipid mediators, and T-cell function","volume":"5","author":"de Jong","year":"2014","journal-title":"Front Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"E2425","DOI":"10.3390\/ijms20102425","article-title":"A role for lipid mediators in acute myeloid leukemia","volume":"20","author":"Loew","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3109\/08820139.2012.695417","article-title":"PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells","volume":"41","author":"Obermajer","year":"2012","journal-title":"Immunol Invest."},{"key":"B75","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1158\/0008-5472.CAN-06-4174","article-title":"Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells","volume":"67","author":"Sinha","year":"2007","journal-title":"Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B77","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10555-018-9754-9","article-title":"Targeting lipid mediators in cancer biology","volume":"37","author":"Sulciner","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B79","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.1208347","article-title":"Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice","volume":"334","author":"Michaud","year":"2011","journal-title":"Science."},{"key":"B83","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1126\/science.aad0779","article-title":"Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1","volume":"350","author":"Vacchelli","year":"2015","journal-title":"Science."},{"key":"B84","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fcell.2019.00050","article-title":"Immunogenic cell death and immunotherapy of multiple myeloma","volume":"7","author":"Serrano-del Valle","year":"2019","journal-title":"Front Cell Dev Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/onc.2010.500","article-title":"Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress","volume":"30","author":"Martins","year":"2011","journal-title":"Oncogene."},{"key":"B87","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene."},{"key":"B90","doi-asserted-by":"publisher","first-page":"41600","DOI":"10.18632\/oncotarget.6113","article-title":"Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies","volume":"6","author":"Gebremeskel","year":"2015","journal-title":"Oncotarget."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1182\/blood-2016-08-731737","article-title":"Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients","volume":"128","author":"Fucikova","year":"2016","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer."},{"key":"B93","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/0008-5472.CAN-07-2531","article-title":"Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells","volume":"68","author":"Heller","year":"2008","journal-title":"Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1172\/JCI69737","article-title":"Predicting response to epigenetic therapy","volume":"124","author":"Treppendahl","year":"2014","journal-title":"J Clin Invest."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-09-0458","article-title":"Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines","volume":"69","author":"Schaefer","year":"2009","journal-title":"Cancer Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41467-018-04518-9","article-title":"RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia","volume":"9","author":"Cheng","year":"2018","journal-title":"Nat Commun."},{"key":"B98","doi-asserted-by":"publisher","first-page":"15621","DOI":"10.18632\/oncotarget.14919","article-title":"The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget."},{"key":"B99","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of non-small cell lung cancer with azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget."},{"key":"B101","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell."},{"key":"B102","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell."},{"key":"B103","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat Commun."},{"key":"B104","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene."},{"key":"B105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"127","author":"Stein","year":"2016","journal-title":"Blood."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2012-09-459313","article-title":"Genomic impact of transient low-dose decitabine treatment on primary AML cells","volume":"121","author":"Klco","year":"2013","journal-title":"Blood."},{"key":"B107","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood."},{"key":"B108","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.15818","article-title":"Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine","volume":"185","author":"Nahas","year":"2019","journal-title":"Br J Haematol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2017-05-780239","article-title":"Phase I clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"131","author":"Nahas","year":"2018","journal-title":"Blood."},{"key":"B110","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","article-title":"Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure","volume":"32","author":"de The","year":"2017","journal-title":"Cancer Cell."},{"key":"B111","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1038\/sj.onc.1203088","article-title":"In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications","volume":"18","author":"He","year":"1999","journal-title":"Oncogene."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/0140-6736(93)92162-M","article-title":"Vitamin A supplementation and childhood morbidity","volume":"342","author":"Semba","year":"1993","journal-title":"Lancet."},{"key":"B114","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.4049\/jimmunol.168.9.4495","article-title":"Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway","volume":"168","author":"Stephensen","year":"2002","journal-title":"J Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"9468","DOI":"10.1073\/pnas.132657799","article-title":"Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia","volume":"99","author":"Westervelt","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B116","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1084\/jem.20030390","article-title":"Retinoids regulate survival and antigen presentation by immature dendritic cells","volume":"198","author":"Geissmann","year":"2003","journal-title":"J Exp Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2172-7-27","article-title":"Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes","volume":"7","author":"Dawson","year":"2006","journal-title":"BMC Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.4049\/jimmunol.179.7.4616","article-title":"All-trans retinoic acid enhances murine dendritic cell migration to draining lymph nodes via the balance of matrix metalloproteinases and their inhibitors","volume":"179","author":"Darmanin","year":"2007","journal-title":"J Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.4049\/jimmunol.1201945","article-title":"Critical role for all-trans retinoic acid for optimal effector and effector memory CD8 T cell differentiation","volume":"190","author":"Allie","year":"2013","journal-title":"J Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/nm949","article-title":"PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia","volume":"9","author":"Padua","year":"2003","journal-title":"Nat Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/blood-2007-08-109009","article-title":"DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model","volume":"115","author":"Furugaki","year":"2010","journal-title":"Blood."},{"key":"B122","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.1158\/0008-5472.CAN-06-1690","article-title":"All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients","volume":"66","author":"Mirza","year":"2006","journal-title":"Cancer Res."},{"key":"B123","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.4049\/jimmunol.1103094","article-title":"Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer","volume":"189","author":"Thomas-Schoemann","year":"2012","journal-title":"J Immunol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2017.1346253","article-title":"Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia","volume":"59","author":"Xu","year":"2018","journal-title":"Leuk Lymphoma."},{"key":"B125","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/CJI.0b013e3181755deb","article-title":"Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide","volume":"31","author":"Kim","year":"2008","journal-title":"J Immunother."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3389\/fimmu.2018.01357","article-title":"Arsenic trioxide enhances the NK cell cytotoxicity against acute promyelocytic leukemia while simultaneously inhibiting its bio-genesis","volume":"9","author":"Alex","year":"2018","journal-title":"Front Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1084\/jem.20150736","article-title":"Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia","volume":"213","author":"Boutzen","year":"2016","journal-title":"J Exp Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41422-019-0162-7","article-title":"Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy","volume":"29","author":"Mugoni","year":"2019","journal-title":"Cell Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0092-8674(89)90241-9","article-title":"Major nucleolar proteins shuttle between nucleus and cytoplasm","volume":"56","author":"Borer","year":"1989","journal-title":"Cell."},{"key":"B130","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood.V93.2.632","article-title":"Detection of normal and chimeric nucleophosmin in human cells","volume":"93","author":"Cordell","year":"1999","journal-title":"Blood."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41588-019-0502-z","article-title":"Germline NPM1 mutations lead to altered rRNA 2\u2032-O-methylation and cause dyskeratosis congenita","volume":"51","author":"Nachmani","year":"2019","journal-title":"Nat Genet."},{"key":"B132","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood."},{"key":"B134","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood."},{"key":"B135","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbmt.2015.10.023","article-title":"Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD","volume":"22","author":"Ho","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B138","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2018","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood-2013-04-496844","article-title":"Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1-mutations (NPM1mut)","volume":"122","author":"Greiner","year":"2013","journal-title":"Blood."},{"key":"B141","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/sj.leu.2404887","article-title":"Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules","volume":"22","author":"Liso","year":"2008","journal-title":"Leukemia."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood."},{"key":"B143","doi-asserted-by":"publisher","first-page":"869","DOI":"10.18632\/oncotarget.26617","article-title":"Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia","volume":"10","author":"Forghieri","year":"2019","journal-title":"Oncotarget."},{"key":"B144","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J Clin Invest."},{"key":"B145","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","article-title":"FLT3 mutations: biology and treatment","volume":"2006","author":"Small","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B146","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1182\/blood-2010-05-283648","article-title":"FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"116","author":"Whitman","year":"2010","journal-title":"Blood."},{"key":"B147","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?","volume":"2013","author":"Levis","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2010-08-301416","article-title":"SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control","volume":"120","author":"Reddy","year":"2012","journal-title":"Blood."},{"key":"B149","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/bloodadvances.2017008227","article-title":"Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv."},{"key":"B151","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1084\/jem.20150642","article-title":"Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses","volume":"213","author":"Lau","year":"2016","journal-title":"J Exp Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00277-011-1231-2","article-title":"Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication","volume":"90","author":"Rickmann","year":"2011","journal-title":"Ann Hematol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00277-013-1744-y","article-title":"Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia","volume":"92","author":"Rickmann","year":"2013","journal-title":"Ann Hematol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell."},{"key":"B155","doi-asserted-by":"publisher","first-page":"17544","DOI":"10.1038\/s41598-018-35978-0","article-title":"Midostaurin reduces regulatory T cells markers in acute myeloid leukemia","volume":"8","author":"Gutierrez","year":"2018","journal-title":"Sci Rep."},{"key":"B156","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lrr.2018.06.003","article-title":"The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant","volume":"10","author":"Li","year":"2018","journal-title":"Leuk Res Rep."},{"key":"B157","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia."},{"key":"B158","doi-asserted-by":"publisher","first-page":"e0190525","DOI":"10.1371\/journal.pone.0209108","article-title":"The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow","volume":"13","author":"Lange","year":"2018","journal-title":"PLoS ONE."},{"key":"B159","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"B160","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell."},{"key":"B162","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2013.12.016","article-title":"Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance","volume":"14","author":"Kats","year":"2014","journal-title":"Cell Stem Cell."},{"key":"B163","doi-asserted-by":"publisher","first-page":"SCI","DOI":"10.1182\/blood.V118.21.SCI-33.SCI-33","article-title":"Epigenetic effects of IDH1\/IDH2 mutations","volume":"118","author":"Melnick","year":"2011","journal-title":"Blood."},{"key":"B164","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood.V124.21.437.437","article-title":"AG-221, a small molecule mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal\/differentiation in IDH2-mutant AML model in vivo","volume":"124","author":"Shih","year":"2014","journal-title":"Blood."},{"key":"B165","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ccell.2016.05.018","article-title":"Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2","volume":"30","author":"Inoue","year":"2016","journal-title":"Cancer Cell."},{"key":"B166","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10545-008-0825-x","article-title":"Membrane translocation of glutaric acid and its derivatives","volume":"31","author":"Muhlhausen","year":"2008","journal-title":"J Inherit Metab Dis."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat Med."},{"key":"B169","doi-asserted-by":"publisher","first-page":"e1445454","DOI":"10.1080\/2162402X.2018.1445454","article-title":"D-2-hydroxyglutarate interferes with HIF-1\u03b1 stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization","volume":"7","author":"B\u00f6ttcher","year":"2018","journal-title":"Oncoimmunology."},{"key":"B170","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1101\/gad.294991.116","article-title":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","volume":"31","author":"Amankulor","year":"2017","journal-title":"Genes Dev."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J Clin Invest."},{"key":"B172","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1073\/pnas.1617929114","article-title":"The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/neuonc\/now061","article-title":"IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression","volume":"18","author":"Zhang","year":"2016","journal-title":"Neuro Oncol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"32428","DOI":"10.1038\/srep32428","article-title":"The oncometabolite R-2-hydroxyglutarate activates NF-kappaB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep."},{"key":"B175","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.cmet.2013.06.019","article-title":"Metabolic regulation by p53 family members","volume":"18","author":"Berkers","year":"2013","journal-title":"Cell Metab."},{"key":"B176","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","article-title":"AMP-activated protein kinase induces a p53-dependent metabolic checkpoint","volume":"18","author":"Jones","year":"2005","journal-title":"Mol Cell."},{"key":"B177","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrm4007","article-title":"p53 in survival, death and metabolic health: a lifeguard with a licence to kill","volume":"16","author":"Kruiswijk","year":"2015","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"a000893","DOI":"10.1101\/cshperspect.a000893","article-title":"p53 Research: the past thirty years and the next thirty years","volume":"2","author":"Lane","year":"2010","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell."},{"key":"B180","doi-asserted-by":"publisher","first-page":"M1","DOI":"10.1016\/S0304-419X(97)00004-8","article-title":"Mutagenesis in the P53 gene","volume":"1333","author":"Pfeifer","year":"1997","journal-title":"Biochim Biophys Acta."},{"key":"B181","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1182\/blood.V124.21.484.484","article-title":"Leukemia associated TP53 mutations in AML patients ARE strongly associated with complex karyotype and poor outcome","volume":"124","author":"Ferrari","year":"2014","journal-title":"Blood."},{"key":"B182","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/leu.2008.375","article-title":"The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia","volume":"23","author":"Seifert","year":"2009","journal-title":"Leukemia."},{"key":"B183","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood."},{"key":"B184","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1182\/blood-2012-03-419622","article-title":"A novel hierarchical prognostic model of AML solely based on molecular mutations","volume":"120","author":"Grossmann","year":"2012","journal-title":"Blood."},{"key":"B185","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2013-12-544957","article-title":"Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"123","author":"Middeke","year":"2014","journal-title":"Blood."},{"key":"B186","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br J Haematol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood.V128.22.3481.3481","article-title":"TP53 mutations in AML predict adverse outcome in patients undergoing allogeneic hematopoietic stem cell transplant","volume":"128","author":"Getta","year":"2016","journal-title":"Blood."},{"key":"B188","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cger.2015.08.010","article-title":"Myelodysplastic syndromes and acute myeloid leukemia in the elderly","volume":"32","author":"Klepin","year":"2016","journal-title":"Clin Geriatr Med."},{"key":"B189","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri.2016.99","article-title":"Emerging roles of p53 and other tumour-suppressor genes in immune regulation","volume":"16","author":"Munoz-Fontela","year":"2016","journal-title":"Nat Rev Immunol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature."},{"key":"B191","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/sj.onc.1208477","article-title":"Resistance to viral infection of super p53 mice","volume":"24","author":"Munoz-Fontela","year":"2005","journal-title":"Oncogene."},{"key":"B192","doi-asserted-by":"publisher","first-page":"e1001360","DOI":"10.1371\/journal.pgen.1001360","article-title":"The Toll-like receptor gene family is integrated into human DNA damage and p53 networks","volume":"7","author":"Menendez","year":"2011","journal-title":"PLoS Genet."},{"key":"B193","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1158\/0008-5472.CAN-11-4134","article-title":"The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells","volume":"72","author":"Shatz","year":"2012","journal-title":"Cancer Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.1128\/MCB.01202-08","article-title":"p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines","volume":"28","author":"Taura","year":"2008","journal-title":"Mol Cell Biol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"E1942","DOI":"10.3390\/ijms17111942","article-title":"Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment","volume":"17","author":"Cui","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B196","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.4161\/cc.10.19.17630","article-title":"Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2","volume":"10","author":"Li","year":"2011","journal-title":"Cell Cycle."},{"key":"B197","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1158\/0008-5472.CAN-10-3211","article-title":"Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2","volume":"71","author":"Textor","year":"2011","journal-title":"Cancer Res."},{"key":"B198","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of activated stellate cells limits liver fibrosis","volume":"134","author":"Krizhanovsky","year":"2008","journal-title":"Cell."},{"key":"B199","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cell.2013.03.020","article-title":"Non-cell-autonomous tumor suppression by p53","volume":"153","author":"Lujambio","year":"2013","journal-title":"Cell."},{"key":"B200","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.celrep.2015.09.045","article-title":"p53 in the myeloid lineage modulates an inflammatory microenvironment limiting initiation and invasion of intestinal tumors","volume":"13","author":"He","year":"2015","journal-title":"Cell Rep."},{"key":"B201","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/bjc.2016.384","article-title":"The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy","volume":"116","author":"Napoli","year":"2017","journal-title":"Br J Cancer."},{"key":"B202","doi-asserted-by":"publisher","first-page":"13301","DOI":"10.1038\/s41598-018-31489-0","article-title":"Characterization of mutations in the mitochondrial encoded electron transport chain complexes in acute myeloid leukemia","volume":"8","author":"Wu","year":"2018","journal-title":"Sci Rep."},{"key":"B203","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(02)00626-8","article-title":"The role of PML in tumor suppression","volume":"108","author":"Salomoni","year":"2002","journal-title":"Cell."},{"key":"B204","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/nrm2277","article-title":"Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies","volume":"8","author":"Bernardi","year":"2007","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fonc.2014.00023","article-title":"A dialog on the first 20 years of PML research and the next 20 ahead","volume":"4","author":"Bernardi","year":"2014","journal-title":"Front Oncol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/35036365","article-title":"The function of PML in p53-dependent apoptosis","volume":"2","author":"Guo","year":"2000","journal-title":"Nat Cell Biol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/35018127","article-title":"PML regulates p53 acetylation and premature senescence induced by oncogenic Ras","volume":"406","author":"Pearson","year":"2000","journal-title":"Nature."},{"key":"B208","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1093\/emboj\/19.22.6185","article-title":"Regulation of p53 activity in nuclear bodies by a specific PML isoform","volume":"19","author":"Fogal","year":"2000","journal-title":"Embo J."},{"key":"B209","doi-asserted-by":"publisher","first-page":"e1074335","DOI":"10.1080\/23723556.2015.1074335","article-title":"Crosstalk between p53 modifiers at PML bodies","volume":"5","author":"Matt","year":"2018","journal-title":"Mol Cell Oncol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nm.3441","article-title":"Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure","volume":"20","author":"Ablain","year":"2014","journal-title":"Nat Med."},{"key":"B211","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12920-017-0249-2","article-title":"Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal acute myeloid leukemia and acute promyelocytic leukemia","volume":"10","author":"Abramowitz","year":"2017","journal-title":"BMC Med Genomics."},{"key":"B212","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","article-title":"Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy","volume":"130","author":"Prokocimer","year":"2017","journal-title":"Blood."},{"key":"B213","doi-asserted-by":"publisher","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci Transl Med."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/ijms20081839","article-title":"Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B215","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv."},{"key":"B216","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","article-title":"Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation","volume":"132","author":"Jacquelin","year":"2018","journal-title":"Blood."},{"key":"B217","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1182\/blood-2010-12-326710","article-title":"AML1\/RUNX1 functions as a cytoplasmic attenuator of NF-\u03baB signaling in the repression of myeloid tumors","volume":"118","author":"Nakagawa","year":"2011","journal-title":"Blood."},{"key":"B218","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/jid.2012.283","article-title":"BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma","volume":"133","author":"Mann","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.1200\/jco.2013.31.15_suppl.9019","article-title":"NRAS mutation: a potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM)","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol."},{"key":"B220","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0022-2275(20)40020-3","article-title":"Cholesterol, phospholipids, and fatty acids of normal immature neutrophils: comparison with acute myeloblastic leukemia cells and normal neutrophils","volume":"20","author":"Klock","year":"1979","journal-title":"J Lipid Res."},{"key":"B221","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbacli.2017.03.002","article-title":"The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features","volume":"7","author":"Pabst","year":"2017","journal-title":"BBA Clin."},{"key":"B222","doi-asserted-by":"publisher","first-page":"e0168781","DOI":"10.1371\/journal.pone.0168781","article-title":"Lipidomic approach for stratification of acute myeloid leukemia patients","volume":"12","author":"Stefanko","year":"2017","journal-title":"PLoS ONE."},{"key":"B223","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2014-08-594408","article-title":"AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress","volume":"125","author":"Sriskanthadevan","year":"2015","journal-title":"Blood"},{"key":"B224","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc3483","article-title":"Cancer metabolism: fatty acid oxidation in the limelight","volume":"13","author":"Carracedo","year":"2013","journal-title":"Nat Rev Cancer."},{"key":"B225","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1172\/JCI62129","article-title":"A metabolic prosurvival role for PML in breast cancer","volume":"122","author":"Carracedo","year":"2012","journal-title":"J Clin Invest."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1096\/fj.02-0541com","article-title":"Characterization of a novel metabolic strategy used by drug-resistant tumor cells","volume":"16","author":"Harper","year":"2002","journal-title":"Faseb J."},{"key":"B227","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1172\/JCI38942","article-title":"Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction","volume":"120","author":"Samudio","year":"2010","journal-title":"J Clin Invest."},{"key":"B228","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"key":"B229","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell."},{"key":"B230","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell."},{"key":"B231","doi-asserted-by":"publisher","first-page":"E3325","DOI":"10.3390\/ijms19113325","article-title":"Stable isotope labeling highlights enhanced fatty acid and lipid metabolism in human acute myeloid leukemia","volume":"19","author":"Stuani","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B232","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1038\/leu.2017.45","article-title":"ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition","volume":"31","author":"Ju","year":"2017","journal-title":"Leukemia."},{"key":"B233","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1038\/s41598-018-23863-9","article-title":"Distinct metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood acute myeloid leukemia","volume":"8","author":"Stockard","year":"2018","journal-title":"Sci Rep."},{"key":"B234","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell."},{"key":"B235","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.2882","article-title":"A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance","volume":"18","author":"Ito","year":"2012","journal-title":"Nat Med."},{"key":"B236","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/0008-5472.CAN-16-1645","article-title":"Bone marrow adipocytes facilitate fatty acid oxidation activating AMPK and a transcriptional network supporting survival of acute monocytic leukemia cells","volume":"77","author":"Tabe","year":"2017","journal-title":"Cancer Res."},{"key":"B237","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fonc.2019.00405","article-title":"Rationale for targeting deregulated metabolic pathways as a therapeutic strategy in acute myeloid leukemia","volume":"9","author":"Chapuis","year":"2019","journal-title":"Front Oncol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"E260","DOI":"10.3390\/cancers11020260","article-title":"Emerging therapies for acute myelogenus leukemia patients targeting apoptosis and mitochondrial metabolism","volume":"11","author":"Castelli","year":"2019","journal-title":"Cancers."},{"key":"B239","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"B240","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1002\/cnr2.1139","article-title":"Metabolic underpinnings of leukemia pathology and treatment","volume":"2","author":"Nemkov","year":"2019","journal-title":"Cancer Rep."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01162\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T21:29:52Z","timestamp":1611782992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01162\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":240,"alternative-id":["10.3389\/fonc.2019.01162"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01162","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"article-number":"1162"}}